Please assess the completion status of the following clinical trial:

Trial Title: Androgen Suppression Plus Radiation Therapy in Treating Patients With Prostate Cancer

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Histologically confirmed adenocarcinoma of the prostate~  * Must have one of the following prognostic factors:~    * Stage T1-2, N0; prostate-specific antigen (PSA) ≤ 10 ng/mL; and Gleason score \> 6~   * Stage T1-2, N0; PSA \> 10 ng/mL and \< 20 ng/mL; and Gleason score ≤ 6~   * Stage T3a, N0; PSA ≤ 10 ng/mL; and Gleason score ≤ 6~* Prostate volume \< 60 cc by transrectal ultrasound~* No distant or nodal metastases~  * No metastatic disease by bone scan, CT scan, or MRI~PATIENT CHARACTERISTICS:~Age:~* 18 and over~Performance status:~* ECOG 0-2~Life expectancy:~* Not specified~Hematopoietic:~* Absolute neutrophil count ≥ 1,500/mm\^3~* Platelet count ≥ 100,000/mm\^3~Hepatic:~* Bilirubin ≤ 1.5 times upper limit of normal~Renal:~* Not specified~Other:~* Fertile patients must use effective contraception~PRIOR CONCURRENT THERAPY:~Biologic therapy:~* No prior immunotherapy for prostate cancer~Chemotherapy:~* No prior chemotherapy for prostate cancer~Endocrine therapy:~* Prior androgen-suppression therapy for up to 4 weeks duration allowed if initiated within 4 weeks of study radiotherapy~* No other prior hormonal therapy~Radiotherapy:~* No prior radiotherapy for prostate cancer~Surgery:~* No prior surgery for prostate cancer~* No prior transurethral resection of the prostate~Other:~* No prior alternative therapy (e.g., PC-SPES) for prostate cancer

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: 120 Years
- Healthy Volunteers: f

Study Arms:
- Androgen suppression + EBRT + Brachytherapy (Type: EXPERIMENTAL): Androgen suppression with external beam radiation therapy followed by brachytherapy boost

Based on this trial design, predict the completion outcome and termination type (if applicable).